Literature DB >> 10136586

Potential drug interactions with H2-receptor antagonists in intensive care unit patients.

M S Monaghan1, L Falls, K M Olsen.   

Abstract

This study's objectives were to identify the incidence of potential histamine-2 receptor antagonist drug interactions in a population of critically ill patients and to identify those at greatest risk for drug interactions. A literature review was completed to identify medications documented to interact when administered concomitantly with histamine-2 receptor antagonists. Data were prospectively collected on 277 consecutive patients admitted into the cardiac care units, medical intensive care units, and surgical intensive care units of two teaching hospitals. The mean age was 55 +/- 16.4 years and one or more organ insufficiency was identified in 52.7% of patients. At least one potential drug interaction was found in 81.6%, with an average of 1.57 potential interactions occurring per patient. Cardiac care unit and medical intensive care unit patients had significantly more potential interactions with drugs having narrow therapeutic indices (P < 0.03). Also, cardiac care unit patients received significantly more medications documented to interact with ranitidine alone or both cimetidine and ranitidine (P < 0.003). Patients admitted to an intensive care unit and receiving a histamine-2 receptor antagonist may require more frequent monitoring because of the potential for drug interactions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 10136586

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  2 in total

1.  Drug-drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US.

Authors:  Pamela L Smithburger; Sandra L Kane-Gill; Amy L Seybert
Journal:  Drug Saf       Date:  2010-10-01       Impact factor: 5.606

Review 2.  Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-Analysis.

Authors:  Mary Grace Fitzmaurice; Adrian Wong; Hannah Akerberg; Simona Avramovska; Pamela L Smithburger; Mitchell S Buckley; Sandra L Kane-Gill
Journal:  Drug Saf       Date:  2019-09       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.